DEZAMIZUMAB: A DEEP INVESTIGATION INTO GSK2398852 AND ITS OUTLOOK

GSK2398852, now known as Dezamizumab, is a innovative monoclonal protein currently under clinical study for its ability to inhibit the enzyme CD22, a crucial regulator of B-cell operation. This treatment approach offers significant prospects for alleviating autoimmune disorders, particularly thos